Erschienen in:
20.07.2016 | Case report
A case of hemorrhagic cystitis caused by nab-paclitaxel
verfasst von:
Emika Ichioka, Akiko Iguchi-Manaka, Takehiro Oikawa, Aya Sawa, Mai Okazaki, Takeshi Saito, Hiroko Kiyomatsu, Tatsuhiko Ikeda, Hiroko Bando, Hisato Hara
Erschienen in:
International Cancer Conference Journal
|
Ausgabe 4/2016
Einloggen, um Zugang zu erhalten
Abstract
Nab-paclitaxel (nab-PTX) is a nanoparticle albumin-bound paclitaxel and, as such, is free of solvents like ethanol and polyoxyethylene castor oil. The absence of solvents from this formulation has several practical advantages: it has a shorter infusion time, it negates the need for premedications for hypersensitivity reactions, and it can be administered to patients with alcoholic hypersensitivity. It is thought that nab-paclitaxel will be in widespread use in the near future because of its convenience and efficacy. Here, we report the case of a breast cancer patient who developed hemorrhagic cystitis potentially due to treatment with nab-paclitaxel. The patient was 69-year old lady with stage IIB left breast cancer. She was due to undergo neoadjuvant chemotherapy and started weekly treatment with nab-paclitaxel. On the second day of the first cycle of treatment, she experienced symptoms of cystitis, but was not hemorrhagic and the symptoms were managed with antibiotics. After the third cycle, the symptoms of cystitis became severe, and she was diagnosed with hemorrhagic cystitis and discontinued chemotherapy with nab-paclitaxel. This is the first case report of hemorrhagic cystitis associated with nab-paclitaxel.